WebIn a preclinical mouse model, intraperitoneal perfusion with cisplatin induced AKI, whereas hyperthermia alone, or in combination with cisplatin, did not induce or enhance renal injury. Amifostine failed to confer nephroprotective effects in a miniaturized HIPEC model. Conclusions: AKI is a frequent complication after HIPEC. The risk of renal ... WebAims: This study investigated the regulatory effect of Mitofusin2 (Mfn2) on mitochondria-associated endoplasmic reticulum membrane (MAMs) integrity and cellular injury in cisplatin-induced acute kidney injury (CP-AKI). Results: CP- AKI mice exhibited decreased expression of Mfn2, increased expression of phosphorylated adenosine …
Frontiers Kidney-Targeted Redox Scavenger Therapy Prevents …
WebMar 29, 2024 · Administration of the chemotherapeutic agent cisplatin leads to acute kidney injury (AKI). Cisplatin-induced AKI (CIAKI) has a complex pathophysiological map, which … WebOct 1, 2024 · Cisplatin is a potent chemotherapeutic used for the treatment of many types of cancer. However, its dose-limiting side effect is nephrotoxicity leading to acute kidney injury (AKI). Patients who develop AKI have an increased risk of mortality and are more likely to develop chronic kidney disease (CKD). flys cheaps
Rapamycin Perfluorocarbon Nanoparticle Mitigates Cisplatin …
WebOct 1, 2024 · Cisplatin is a potent chemotherapeutic used for the treatment of many types of cancer. However, its dose-limiting side effect is nephrotoxicity leading to acute kidney injury (AKI). Patients who develop AKI have an increased risk of mortality and are more likely to develop chronic kidney disease (CKD). WebPurpose: Cisplatin-induced acute kidney injury (CIA) is a serious adverse event that affects 20-40% of exposed patients, despite any implemented precaution to avoid it. The aim of this work was therefore to identify a relevant nephroprotective method for CIA. Methods: We searched Pubmed, Embase, and Web of Science from 1 January 1978 to 1 June … WebAug 12, 2024 · In AKI, studies have shown that IL-10 can protect against ischemia, cisplatin, or ureteric obstruction–induced renal injury by limiting inflammatory cytokine production and immune cell infiltration ( 4, 5 ), indicating that IL-10 may be a potential therapy to tackle the current clinical challenges of AKI treatment. flyschoidi